How to successfully commercialise microbiome-based diagnostics
In this Med-tech Innovation News article, Andrew Thomson, Brian Carpenter and Robert Broadnax explore key drivers of adoption of microbiome-based diagnostics,...
Brian Carpenter is a principal in the Life Sciences Practice of CRA. He has more than 10 years of experience in commercial strategy within the life sciences industry, including diagnostics, therapeutics, and medical devices.
His focus is on product and therapeutic area strategy across the product lifecycle (e.g. launch planning, competitive intelligence/simulation, landscape and opportunity assessments, etc.) as well as portfolio strategy (e.g. portfolio optimization, asset due diligence, etc.). He has a breadth of experience across neurology, immunology, oncology and specialty biotech, leveraging market research and advanced analytics where needed to support insight generation.
Prior to joining CRA, he was a program manager at Vermillion, an ovarian cancer diagnostic company, leading the development and delivery of a next generation diagnostic as well as clinical utility and health economics studies to support payer coverage decisions.